Merck's Isentress approved for treatment-naïve HIV patients in EU
This article was originally published in Scrip
Executive Summary
The European Commission has granted Merck & Co's first-in-class HIV integrase inhibitor Isentress (raltegravir) a label expansion to include treatment-naïve adult patients.